Clinical trial
Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent…
NCT00004865 · Jonsson Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00004865 |
|---|---|
| Title | Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy |
| Official title | Phase II Study of Cetuximab Anti-Epidermal Growth Factor Receptor (EGFr) Antibody in Combination With Chemotherapy in Patients With Metastatic or Recurrent Squamous Cell Head and Neck Carcinoma |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH Eli Lilly and Company Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Biological, Drug |
| Interventions | cetuximab, cisplatin, fluorouracil, paclitaxel |
| Start date | Nov 1, 1999 |
| Primary completion | Jan 1, 2002 |
| First posted | Mar 16, 2004 |
| Last update posted | Mar 9, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: